KLRA vs KMDA

Kailera Therapeutics, Inc. vs Kamada Ltd. — Valuation Comparison 2026

KLRA

Pharmaceutical Preparations
Kailera Therapeutics, Inc.
Quality
1.7
out of 10
Value Trap
Price
$22.94
Last close
Models
5/13
Active
VS

KMDA

Pharmaceutical Preparations
Kamada Ltd.
Quality
1.9
out of 10
Value Trap
Price
$7.81
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType KLRA Fair ValueKLRA Upside KMDA Fair ValueKMDA Upside
Bayesian DCF Intrinsic $5.97 -74.0% $2.08 -73.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $3.86 -53.3%
ML-RIV Intrinsic $3.09 -86.5% $6.70 -14.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KLRA vs KMDA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KLRA vs KMDA — Which Stock Is More Undervalued?

KMDA scores higher with a 1.9/10 quality rating vs KLRA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kailera Therapeutics, Inc. (KLRA) and Kamada Ltd. (KMDA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KLRA currently trades at $22.94 with a QOC of 1.7/10, while KMDA trades at $7.81 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).